ArticleInvestigational new drugs2023

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.

Shintaro Takaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.